penpulimab

Penpulimab is a humanized IgG1 monoclonal antibody that targets the programmed cell death 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2. This blockade restores T-cell-mediated immune responses against tumor cells, enhancing antitumor immunity. Penpulimab is engineered with Fc region modifications to eliminate Fcγ receptor binding and Fc-mediated effector functions, reducing the risk of immune-related adverse effects such as antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis. It demonstrates a slower dissociation rate from PD-1 compared to other inhibitors, resulting in higher receptor occupancy and enhanced T-cell activity. Developed by Akeso Biopharma in collaboration with Chia Tai Tianqing Pharmaceutical Group, penpulimab is approved for relapsed or refractory classic Hodgkin's lymphoma, recurrent/metastatic nasopharyngeal cancer (NPC), and locally advanced/metastatic squamous non-small cell lung cancer (NSCLC). It is also under review for hepatocellular carcinoma and being studied in various other solid tumors.

Brand names

安尼可Anniko

Other names

penpulimab